麻杏石甘汤合理剂量对小儿支气管肺炎疗效的关键作用:三项随机双盲剂量平行对照试验
三项随机双盲多中心试验各纳入120例风热闭肺型支气管肺炎患儿,按1:1:1分为低、中、高剂量组,分别调整麻杏石甘汤总量、石膏剂量和苦杏仁剂量,干预10天。结果表明基础临床剂量可能已是最优,剂量不足影响疗效,增量未显著增效;不同症状可针对性调整石膏或苦杏仁剂量。
要点
- 麻杏石甘汤基础临床剂量治疗小儿支气管肺炎可能为最优剂量。
- 总量中、高剂量组治愈率显著高于低剂量组,但中高剂量间无显著差异。
- 增加石膏剂量可改善发热、咳嗽、呼吸困难;增加苦杏仁剂量改善咳嗽、痰壅。
核心结论
- 麻杏石甘汤基础临床剂量可能是风热闭肺型支气管肺炎患儿的最优干预剂量。
- 剂量不足可能影响临床疗效,但提高剂量未显著增强获益。
- 针对不同症状,增加石膏剂量有助于改善发热、咳嗽、呼吸困难,增加苦杏仁剂量有助于缓解咳嗽和痰壅。
研究设计与样本
- 三项随机、双盲、剂量平行对照、多中心临床试验,分别调整麻杏石甘汤总量、石膏剂量和苦杏仁剂量。
- 每项试验纳入120例风热闭肺型支气管肺炎患儿,按1:1:1分为低、中、高剂量组,每组40例,干预10天。
- 主要结局为临床治愈率,次要结局包括发热、咳嗽、呼吸困难、痰壅等症状缓解情况及不良事件。
主要发现
- 总量调整试验:中剂量组和高剂量组临床治愈率显著高于低剂量组(卡方值9.01,p=0.0111),高剂量组与中剂量组无显著差异(81.58% vs. 81.08%)。
- 总量调整试验:除发热、咳嗽、呼吸困难外,中剂量组和高剂量组痰壅临床治愈率显著高于低剂量组(卡方值6.31,p=0.0426),高剂量组与中剂量组无显著差异(69.23% vs. 75.00%)。
- 石膏剂量调整试验:高剂量组临床治愈率最高,但组间差异无统计学意义(卡方值3.36,p=0.1864);中剂量组咳嗽AUC显著低于低剂量组和高剂量组(F值3.14,p=0.0471)。
- 石膏剂量调整试验:高剂量组(p<0.0001)和中剂量组(p=0.0015)完全退热时间均快于低剂量组,高剂量组略优于中剂量组(0.50(0.50, 0.80) vs. 0.80(0.40, 1.40)),但差异无统计学意义。
- 苦杏仁剂量调整试验:中剂量组和高剂量组治愈率显著高于低剂量组(卡方值47.05,p<0.0001),高剂量组与中剂量组无显著差异(90.00% vs. 92.50%);咳嗽(F值3.16,p=0.0460)和痰壅(F值3.84,p=0.0243)的AUC中、高剂量组均显著低于低剂量组。
关键数值与推荐
- 总量调整试验:中剂量组与高剂量组临床治愈率分别为81.58%和81.08%,均显著高于低剂量组(卡方值9.01,p=0.0111)。
- 总量调整试验:中剂量组与高剂量组痰壅临床治愈率分别为69.23%和75.00%,均显著高于低剂量组(卡方值6.31,p=0.0426)。
- 石膏剂量调整试验:高剂量组和中剂量组完全退热时间均快于低剂量组(高剂量组p<0.0001,中剂量组p=0.0015)。
- 苦杏仁剂量调整试验:中剂量组和高剂量组治愈率分别为92.50%和90.00%,均显著高于低剂量组(卡方值47.05,p<0.0001)。
临床怎么用
- 临床使用麻杏石甘汤治疗小儿支气管肺炎(风热闭肺)时,可优先采用基础临床剂量,不宜盲目增加总量。
- 若患儿痰壅症状突出,可考虑适当增加麻杏石甘汤总量。
- 若患儿发热、咳嗽、呼吸困难症状突出,可在安全范围内考虑增加石膏剂量。
- 若患儿咳嗽、痰壅症状明显,可在安全范围内考虑增加苦杏仁剂量。
局限性
- 研究为探索性临床试验,结论尚需进一步研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: Evaluate the impact of adjusting the overall dose, Gypsum Fibrosum [Mineral; Gypsum] (ShiGao, SG) dose, and Prunus armeniaca L. [Rosaceae; Semen Armeniacae Amarum] (KuXingRen, KXR) dose on the efficacy of MaXingShiGan Decoction (MXSG) in treating children with bronchial pneumonia (Wind-heat Blocking the Lung), in order to provide strategy supported by high-quality evidence for the selection of rational clinical doses of MXSG. Methods: Based on the basic dose of MXSG, we conducted three randomized, double-blind, dose parallel controlled, multicenter clinical trials, involving adjustments to the overall dose, SG dose, and KXR dose, and included 120 children with bronchial pneumonia (Wind-heat Blocking the Lung) respectively. And the patients were divided into low, medium, and high dose groups in a 1:1:1 ratio, with 40 cases in each group. The intervention period lasted for 10 days. The primary outcome was the clinical cured rate, while the secondary outcomes included the effectiveness in alleviating major symptoms of bronchial pneumonia (including fever, cough, dyspnea, and phlegm congestion). And the occurrence of adverse events was recorded. Results: We first recorded and analyzed the baseline characteristics of the three studies, including age, gender, height, and so on. The results indicated that there were no significant differences among the dose groups within each study. For the study adjusting the overall dose of MXSG, the results showed that both the medium-dose group and high-dose group had significantly higher clinical cured rates compared to the low-dose group (Chi-square value 9.01, p = 0.0111). However, there was no significant benefit between the high-dose group and the medium-dose group (81.58% vs. 81.08%). Regarding phlegm congestion, excluding fever, cough, and dyspnea, both the medium-dose group and high-dose group had significantly higher clinical cured rates than the low-dose group (Chi-square value 6.31, p = 0.0426), and there was no significant benefit between the high-dose group and the medium-dose group (69.23% vs. 75.00%). A total of 5 adverse events were observed, of which only 1 case in the medium-dose group was possibly related to the experimental medication. For the study adjusted the SG dose in MXSG, the results showed that the high-dose group had the highest clinical cured rate, but the inter-group difference was not statistically significant (Chi-square value 3.36, p = 0.1864). The area under the curve (AUC) for cough in the medium-dose group was significantly lower than in the low-dose group and high-dose group (F-test value 3.14, p = 0.0471). Although no significant differences were observed in fever and dyspnea among the groups, the AUC in the high-dose group was lower than in the medium-dose and low-dose groups. In comparing the complete defervescence time, both the high-dose group (p < 0.0001) and the medium-dose group (p = 0.0015) achieved faster than the low-dose group. The high-dose group slightly outperformed the medium-dose group (0.50 (0.50, 0.80) vs. 0.80 (0.40, 1.40)), although the difference was not significant. In the medium-dose group, 1 adverse event was observed, but it was not related to the experimental medication. For the study adjusted the KXR dose in MXSG, the results showed that both the medium-dose group and high-dose group had significantly higher cured rates compared to the low-dose group (Chi-square value 47.05, p < 0.0001). However, there was no significant benefit comparing the high-dose group to the medium-dose group (90.00% vs. 92.50%). Regarding clinical symptoms, the results indicated that for cough (F-test value 3.16, p = 0.0460) and phlegm congestion (F-test value 3.84, p = 0.0243), the AUC for both the medium-dose group and high-dose group were significantly lower than in the low-dose group. Although there was benefit in the high-dose group compared to the medium-dose group, it was not statistically significant. No adverse events were observed during the study period. Conclusion: The synthesis of the three conducted clinical studies collectively indicates that for children with bronchial pneumonia (Wind-heat Blocking the Lung), the basic clinical dose of MXSG may represents an optimal intervention dose based on the accumulated clinical experience of doctors. If the dose is insufficient, the clinical effects might be compromised, but using a higher dose does not significantly enhance benefits. Concerning different symptoms, increasing the overall formula's dose has a favorable impact on improving phlegm congestion, increasing the SG is effective in improving symptoms such as fever, cough, and dyspnea, while higher dose of KXR is effective in alleviating cough and phlegm congestion. These findings suggest that for MXSG, achieving the optimal intervention dose is crucial to achieve better clinical efficacy. For the SG and KXR, if certain symptoms are more severe, increasing the dose can be considered within safe limits, can lead to significant clinical benefits in symptom improvement. This also explains why the dose of MXSG might vary among clinical doctors, while maintaining a balance between safety and effectiveness. Of course, our study is still exploratory clinical trials, and further studies are needed to confirm our findings. Clinical Trial Registration: https://www.chictr.org.cn/index.html; Identifier: ChiCTR-TRC-13003093, ChiCTR-TRC-13003099.
引用
- An X, Shi C, Han Y, et al. The rational dose for MaXingShiGan decoction is crucial for its clinical effectiveness in treating bronchial pneumonia: three randomized, double-blind, dose-parallel controlled clinical studies. Front Pharmacol. 2023. PMID: 38074138. doi:10.3389/fphar.2023.1279519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。